Six regulators read the same British document and reach six different conclusions — from waiving the factory visit outright to charging thirty thousand pounds to make it anyway. Membership of the same international inspection scheme predicts almost none of it.
A UK manufacturer filing a medicine abroad expects to pay a registration fee. What catches people is the other number: whether the target regulator will send inspectors to the factory, and what that costs. In Nigeria a foreign inspection is roughly nine times the registration fee it accompanies. In Türkiye it is roughly twice a new-molecule application.
So the practical question is not "is my site compliant". It is "will this particular authority accept the certificate I already hold, and on what published authority". That turns out to have six different answers, and the intuition almost everyone brings to it — that membership of the same international inspection scheme means certificates travel — is wrong often enough to be dangerous.
A site in one of EDA's twenty-four reference countries — the United Kingdom is third on the list — is waived from on-site inspection altogether. In the authority's own words, imported medicinal products from reference countries are "waived from EDA on-site inspection as a prerequisite for approving the manufacturing site. Whereas EDA shall only review the site valid GMP certificate." No visit and no inspection fee.
Waived outrightA documentary route exists. GMP approval may be granted on a certificate from a recognised regulator issued within the previous three years, where the dosage-form grouping, product type and applied-for activities match. Recognised regulators are the scheme's member authorities, WHO, and the regional collaborative procedure — so an MHRA certificate is in scope. SAHPRA reserves the right to ask for more, or to inspect.
Documentary routeTwo forms of relief, both conditional. The reliance guideline permits NAFDAC to rely on inspection and audit reports not more than three years old, through a facility status verification. Separately the tariff prices a risk-based desk review at US$5,000 for a site that has already been inspected — a second-product economy, not a first-entry waiver. Absent either, the inspection is US$10,989 per site and the applicant must write the letter inviting it.
Reliance, conditionalA legalised current GMP certificate from the competent authority in the country of origin is part of the dossier, and EDE issues its own GMP certificate at AED 2,000 per line per year. Whether EDE inspects foreign sites, and on what trigger, we could not establish from a published source. That is not the same as saying it does not. It means nobody should budget for either answer.
Not publishedAn MHRA or EU certificate satisfies the origin-country requirement on the face of the dossier. What it does not do is remove the authority's own right of inspection: the rules state that "The SFDA inspects the manufacturer to ensure the implementation of Good Manufacturing Practice" and that it may assign a technical team to do so. There is no mutual recognition agreement, and no published list of authorities whose certificate substitutes for a visit.
Right reservedThe most explicit of the six, and the least forgiving. Scheme membership buys a certificate life of twelve years against nine, and three risk-based renewals against two. It does not buy exemption from the first on-site inspection. The desktop assessment route that once offered an alternative was abolished on 6 October 2023 and has not been reinstated.
Inspects regardlessOrdered by how much of the inspection burden the regulator removes, not by preference. Each row is traced on that market's own page, with the document, its version and the date we checked it.
The Pharmaceutical Inspection Co-operation Scheme is the obvious thing to reason from. Its whole purpose is harmonised inspection standards and mutual confidence between authorities, the MHRA has been in it since 1971, and four of our six markets are in it or approaching it. If membership meant certificates travelled, the spectrum above would sort itself neatly by accession date.
| Authority | Scheme status | What it is worth for a UK site |
|---|---|---|
| MHRA, United Kingdom | Member since 1971 Scheme, 1999 | The certificate you are trying to travel on |
| SAHPRA, South Africa | July 2007 | A documentary GMP approval, no visit, subject to conditions |
| TİTCK, Türkiye | January 2018 | A longer certificate life. Not exemption from the first inspection |
| SFDA, Saudi Arabia | May 2023 | A better starting position for a conversation. No published entitlement |
| NAFDAC, Nigeria | Pre-applicant rapporteur Aug 2025 | Reliance on a report under three years old — under its own directive, not the scheme |
| EDA, Egypt | Applied for pre-accession September 2023 | The most generous waiver of all six — and it owes nothing to the scheme |
| EDE, United Arab Emirates | Not established | Unknown |
Türkiye has been a member alongside the MHRA since 2018 and will still send inspectors to your factory and bill you roughly thirty thousand pounds for the privilege. Egypt is not a member at all — it only applied for pre-accession in September 2023 — and waives the visit outright for a British site. The membership list and the outcome list are not the same list. Whatever your regulatory affairs manager remembers about mutual recognition, the operative document is the target authority's own reliance guideline, and it has to be read each time.
There is a reason for this that is worth understanding rather than resenting. The scheme harmonises how inspections are done; it does not oblige any participating authority to accept another's conclusions. Recognition is a separate, unilateral policy decision that each authority makes in its own instrument — which is exactly why Egypt, owing the scheme nothing, can be more generous than a member.
Converted to sterling for comparison at the rates below. The figures that matter here are not the heights of the bars. They are how few bars there are.
Read the empty bars, not the full ones. Four of the six do not publish a number a UK finance director could put in a plan. That is not a gap in our research — it is the state of the published record, and it is why the largest line in a medicines budget is routinely absent from the quotes companies are given. A provider who hands you a single inclusive figure for a Saudi or Emirati project has either confirmed the inspection cost privately with the authority, in which case ask to see it, or has guessed.
Two of these regulators, working from unrelated instruments, arrived at the same shelf life for a certificate or report they are willing to lean on.
GMP approval without an on-site inspection where the site was approved by a recognised regulator within the previous three years, and the dosage-form grouping, product type and activities match
Reliance permitted on inspection reports, audit reports and bridging reports which shall not exceed 3 years validity. Separately, a NAFDAC foreign facility inspection is itself valid three years
Runs the other way: a certificate from a scheme-member site gets a twelve-year life against nine, with three risk-based renewals against two — a long life for a certificate you must still be inspected to obtain
Your MHRA certificate has one validity for British purposes and a different, shorter one for reliance purposes abroad. A site inspected by the MHRA thirty-four months ago is a different commercial proposition from the same site inspected last week — and the difference is measured in five figures per market. If you are sequencing three markets, the order should be chosen so that the reliance window covers all three, and that is a scheduling decision made a year before anyone files anything.
Every statement above comes from one of the following. We give the article or section because in this area the wrong citation is worse than none — several of these authorities publish superseded guidance that consultancies still quote as current.
Guidelines on Reliance Practices During Registration of Medicinal Products, issued and effective 11 August 2024. The reference-country list itself is NP.CAPP.089, version 1/2024, effective 1 July 2024, with the United Kingdom third of twenty-four.
Guidelines to Good Manufacturing Practice for Medicines, effective 13 April 2026, including Appendix 1 on recognised regulators. The reliance framework itself is SAHPGL-BAU-01 v5, effective 6 August 2025, §9.1.
Reliance guideline effective 25 September 2025 — the three-year report validity and facility status verification. Fees from the NAFDAC tariff effective 31 January 2020, Section D, including note D 8.0 on the risk-based desk review.
Dated 22 September 2025 — certificate validity of twelve years for scheme-country sites against nine, three risk-based renewals against two, and the abolition of the desktop assessment route on 6 October 2023. Fees from the TİTCK tariff of 23 March 2026.
The manufacturer registration chapter, which requires a GMP certificate from the authority in the country of origin with proof of inspection, a site master file and inspection fees — and which states the Authority's own inspection right in terms.
Official Gazette 785 of 14 October 2024, in force 2 January 2025, article 6 on assessment and good manufacturing practice, read with EDE's published service pages for manufacturer registration and the GMP certificate.
The Pharmaceutical Inspection Co-operation Scheme's own register of participating authorities and its accessions and pre-applicants page, which is the authoritative source for who is a member and since when.
Neither the decree-law nor the published service pages say. We looked for a trigger, a fee and a procedure and found none of the three. This is the single largest unknown on the page.
The rules require inspection fees with the manufacturer registration file. The amounts we located come from an administrative decision of 2011 that SFDA still hosts, and we found nothing newer. We do not publish them.
The hourly rate and the desktop day rate reach us through a secondary compilation of the February 2025 fee regulation, because the gazette is published as a scanned image with no readable text layer. Travel is reimbursed on top and cannot be estimated from public sources.
EDA's Arabic service catalogue carries a line for foreign factory inspection priced by continent, and no visible amounts against it.
Not one of the six publishes a waiting time for a foreign inspection, a position in a queue, or a service standard for arranging one. On the critical path of a first medicines filing this is usually the longest item and it is the least visible.
Everything stated as fact above was read from the regulator's own document or from the scheme's own register. Where a figure reaches us through a reproduction or a compilation rather than the primary instrument, the line says so.
Not "is it certified". The date and the authority, because two of these regulators count backwards three years from today and one of them counts the certificate's own life. A site inspected thirty-four months ago and the same site inspected last month are different commercial propositions.
Your quality team, in an afternoonEgypt's waiver attaches to the country of the site, not to the country of your marketing authorisation. A UK holder manufacturing in India loses it. This single fact reorders a sequencing plan more often than anything else on this page.
Us, in a dayEvery relief described above lives in a named guideline with a version number, and several of them changed in 2025 or 2026. The desktop route Türkiye offered until October 2023 is still being quoted by advisers today. Cite the current instrument or expect to argue.
Us, with the citationThe six medicines market pages each carry this in full for their own regulator, with the fees, the clocks and the sections we could not confirm: Saudi Arabia · United Arab Emirates · Egypt · Türkiye · Nigeria · South Africa.
Send us the site, its last inspection date and the markets you are weighing. We will tell you which of the six will accept the certificate you already hold, which will not, and what the difference costs — with the clause that decides it in each case.
Or reach us directly — mail@bcabusiness.co.uk · +44 7342 901002 · WhatsApp
Re-checked quarterly, and immediately on any change to a reliance guideline or to the scheme's membership. Sterling conversions are indicative and were made on the date of publication. This article covers medicines; the equivalent question for medical devices is a different one with different answers, and it is treated on the device pages.